Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases
April 24, 2024 07:00 ET
|
Biolojic Design
Nektar Therapeutics Has Exercised Its License Option to Develop Biolojic Design's AI-Designed Antibody Targeting TNFR2 in Immunology
Biolojic Design Enters a Research Collaboration and License Option Agreement with Nektar Therapeutics to Develop Computationally Designed Antibodies Against a Novel Target for the Potential Treatment of Autoimmune Disease
February 25, 2021 07:00 ET
|
Biolojic Design
TEL AVIV, Israel, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Biolojic Design (“Biolojic”), a biotechnology company that computationally designs functional antibodies, today announced that it has entered into...